Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

nd solid tumors. The IMiDs pipeline is covered by a comprehensive intellectual property estate of U.S. and foreign issued and pending patent applications including composition-of- matter and use patents.

About Multiple Myeloma

Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease remains unknown.

About RevAssist(R)

FOR FURTHER INFORMATION ABOUT REVLIMID AND RevAssist, A RESTRICTED DISTRIBUTION PROGRAM USED IN THE UNITED STATES, YOU MAY GO TO THE INTERNET AT www.REVLIMID.com OR BY CALLING THE MANUFACTURER'S TOLL FREE NUMBER 1-888- 4CELGENE. RevAssist is a proprietary risk-management restrictive distribution program, tailored specifically for REVLIMID patients, to prevent the potential for human birth defects and ensure prompt and convenient access to REVLIMID through contracted pharmacies.

About ECOG

The Eastern Cooperative Oncology Group (ECOG) was established in 1955 as one of the first cooperative groups launched to perform multi-center cancer clinical trials. A cooperative group is a large network of researchers, physicians, and health care professionals at public and private institutions across the country who are members of the group. Funded primarily by the National Cancer Institute (NCI), ECOG has evolved from a five member consortium
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/4/2008)...wswire/ -- Southern Research Institute,today annou...has selected,the organization to participate in th...n Center Network (MLPCN). The MLPCN -- a collabora...Libraries Program which is,designed to benefit hum...an,genome and validate future targets for drug dis...
(Date:9/4/2008)...or Ipilimumab to be Presented, PRINCETON, N.J., S...sdaq: MEDX ) announced today that nine clinical a...TLA-4 antibody, in melanoma are scheduled to be,th... the European Society,for Medical Oncology (ESMO) ...y of the following abstracts will include updated ...
(Date:9/4/2008)...edule with Two Abstracts Accepted for Presenta...2008, BRIDGEWATER, N.J., Sept. 4 /- ...ceutical company focused on the treatment of,cardi...he appointment of,Peter L. Garrambone, Jr. to the ... career includes more than 50 pharmaceutical,trans...
(Date:9/3/2008)...wire-FirstCall/ -- Simcere,Pharmaceutical Group (N...f,branded generic pharmaceuticals and manufacturer...(also known as Endostar) in China,announced the i...At the request of the SFDA, Simcere initiated a Ph...ty and therapeutic efficacy of Endu, a modified,ve...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 1Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 2Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 3People with obstructive sleep apnea at risk for cardiac stress on airline flights 19674 1People with obstructive sleep apnea at risk for cardiac stress on airline flights 19674 2Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 1Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 2Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 3Sen Edward Kennedy Hospitalized After Seizure 19669 1Sen Edward Kennedy Hospitalized After Seizure 19669 2
...ignificantly,increases patients_ overall survival ...ublished,yesterday in the Journal of Clinical Onco...) was shown to significantly improve,survival in p...chemotherapy alone.1 Follicular lymphoma is the mo...ssing but incurable form of,lymphoma. , The study ...
...ed with,Exforge achieved recommended blood pressur...Hg in,systolic blood pressure observed in patients... monotherapy[1] , Nearly 70% of those with high b...d most require two or more,medications to achieve ... - Exforge®,a single-tablet combination of tw...
Other Medicine Technology:Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 3Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8
(Date:9/4/2008).... Free drug samples provided to physicians by pha...insured patients more in the long run, according t...rsity Baptist Medical Center and colleagues. , T...abits of more than 70 physicians in a university-a... immediately before and after the closing of their...
(Date:9/4/2008)...n a case-control study, the presence of measles vi... and GI disturbances than in children with only GI... onset were unrelated to MMR vaccine timing. Stud...ary of Science on September 4 ( http://dx.plos.or... implementation of measles vaccines in 1963, three...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)...ger labeling about fungal infection risk , ...l health authorities have asked the manufacturers ...ster safety warnings on the risk of developing opp...ra, Cimzia, Enbrel and Remicade, belong to a class...ha blockers (TNF-alpha blockers), which suppress t...
Breaking Medicine News(10 mins):Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...olocaust are more likely to suffer from cancer and...d his colleagues at Israel's //Haifa University su...ear-starvation of European Jews during World War I...at the incidence and death rate from cancer in aro...
... of Goan’s can be the main cause for HIV/AIDS spre...ollow the Government policies // and initiatives t...Many labourers who got jobs in Goa, since it has b...ing with them the dreadful virus (HIV) when they a...
...er gave Isabelle Taylor, of St Annes, Lancs, a mob... grand child would end up constantly // sending te...loping a condition known as ‘repetitive strain in...n in Britain to suffer from this condition. Her m...
... researchers plan to ask women to donate their egg... cells matched to patients // which they say would...ng diseases such as diabates or neurodegenerative ...nic stem (ES) cells after creating human embryos c...
Other Medicine News:
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: